From July 1, 2023 to September 30, 2023, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 18,227,779 shares, representing 25.26% for $588.23 million under the buyback announced on November 5, 2013.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.35 USD | -1.80% | -3.50% | +16.77% |
05-31 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
05-31 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.77% | 2.02B | |
-4.32% | 12.39B | |
-0.60% | 8.43B | |
+6.91% | 5.77B | |
-10.21% | 4.1B | |
-60.35% | 2.66B | |
+10.62% | 2.66B | |
-7.86% | 2.39B | |
-9.18% | 1.77B | |
-2.30% | 1.51B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Tranche Update on Myriad Genetics, Inc.'s Equity Buyback Plan announced on November 5, 2013.